EP0318446A1 - Aminosäure-Zusammensetzung als Träger für die parenterale Ernährung - Google Patents
Aminosäure-Zusammensetzung als Träger für die parenterale Ernährung Download PDFInfo
- Publication number
- EP0318446A1 EP0318446A1 EP88850373A EP88850373A EP0318446A1 EP 0318446 A1 EP0318446 A1 EP 0318446A1 EP 88850373 A EP88850373 A EP 88850373A EP 88850373 A EP88850373 A EP 88850373A EP 0318446 A1 EP0318446 A1 EP 0318446A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- composition
- glutamine
- optionally
- alpha
- ketoglutarate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- 150000001413 amino acids Chemical class 0.000 title claims abstract description 35
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 21
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims abstract description 34
- 229940024606 amino acid Drugs 0.000 claims abstract description 34
- 235000001014 amino acid Nutrition 0.000 claims abstract description 34
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims abstract description 30
- KPGXRSRHYNQIFN-UHFFFAOYSA-L 2-oxoglutarate(2-) Chemical compound [O-]C(=O)CCC(=O)C([O-])=O KPGXRSRHYNQIFN-UHFFFAOYSA-L 0.000 claims abstract description 22
- 229930182816 L-glutamine Natural products 0.000 claims abstract description 19
- 229960001230 asparagine Drugs 0.000 claims abstract description 16
- WDJHALXBUFZDSR-UHFFFAOYSA-M acetoacetate Chemical compound CC(=O)CC([O-])=O WDJHALXBUFZDSR-UHFFFAOYSA-M 0.000 claims abstract description 15
- 230000002980 postoperative effect Effects 0.000 claims abstract description 14
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 11
- 150000002148 esters Chemical class 0.000 claims abstract description 10
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- 239000000843 powder Substances 0.000 claims abstract description 7
- 239000007864 aqueous solution Substances 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims description 4
- 159000000000 sodium salts Chemical class 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 abstract description 15
- 235000015097 nutrients Nutrition 0.000 abstract description 9
- 238000002360 preparation method Methods 0.000 abstract description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
- 239000004475 Arginine Substances 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 abstract 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 abstract 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 abstract 1
- 239000004473 Threonine Substances 0.000 abstract 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 abstract 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 1
- 235000004279 alanine Nutrition 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 229940009098 aspartate Drugs 0.000 abstract 1
- 235000018417 cysteine Nutrition 0.000 abstract 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
- 229960003067 cystine Drugs 0.000 abstract 1
- 229930195712 glutamate Natural products 0.000 abstract 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
- 229960000310 isoleucine Drugs 0.000 abstract 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 abstract 1
- 229930182817 methionine Natural products 0.000 abstract 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 1
- 229960005190 phenylalanine Drugs 0.000 abstract 1
- 235000008729 phenylalanine Nutrition 0.000 abstract 1
- 239000004474 valine Substances 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 40
- 229910052757 nitrogen Inorganic materials 0.000 description 20
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 15
- 210000002027 skeletal muscle Anatomy 0.000 description 11
- 230000037396 body weight Effects 0.000 description 10
- 208000014674 injury Diseases 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 238000001243 protein synthesis Methods 0.000 description 8
- 230000014616 translation Effects 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 230000003834 intracellular effect Effects 0.000 description 6
- 210000003445 biliary tract Anatomy 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 108010023197 Streptokinase Proteins 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- VUTGNDXEFRHDDC-UHFFFAOYSA-N 2-chloro-n-(2,6-dimethylphenyl)-n-(2-oxooxolan-3-yl)acetamide;2-(trichloromethylsulfanyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(SC(Cl)(Cl)Cl)C(=O)C2=C1.CC1=CC=CC(C)=C1N(C(=O)CCl)C1C(=O)OCC1 VUTGNDXEFRHDDC-UHFFFAOYSA-N 0.000 description 3
- 239000003792 electrolyte Substances 0.000 description 3
- 125000000468 ketone group Chemical group 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- SLPUVFBNQHVEEU-WCCKRBBISA-N (2s)-2,5-diaminopentanoic acid;2-oxopentanedioic acid Chemical compound NCCC[C@H](N)C(O)=O.OC(=O)CCC(=O)C(O)=O SLPUVFBNQHVEEU-WCCKRBBISA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000002283 elective surgery Methods 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 229940028435 intralipid Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 235000016236 parenteral nutrition Nutrition 0.000 description 2
- 210000002729 polyribosome Anatomy 0.000 description 2
- 230000022558 protein metabolic process Effects 0.000 description 2
- 239000000700 radioactive tracer Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 206010002942 Apathy Diseases 0.000 description 1
- 208000034657 Convalescence Diseases 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- 241001254607 Leander Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010051508 Preconativ Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 238000012084 abdominal surgery Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- -1 glucose and the like Chemical class 0.000 description 1
- 150000002308 glutamine derivatives Chemical class 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229940075858 ornithine alpha-ketoglutarate Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000021476 total parenteral nutrition Nutrition 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 208000016254 weariness Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Definitions
- the present invention relates to a composition for therapeutic, especially postoperative and posttraumatic, parenteral nutritional support treatment, which composition, in addition to conventional amino acid components, also contains L-glutamine and/or its derivative alpha-ketoglutarate, and optionally L-asparagine and acetoacetate.
- parenteral nutritional support In severe states of illness and injuries, and in postoperative states, parenteral nutritional support is generally applied.
- preparations for intraveneous nutritional support generally contained an aqueous solution of a high caloric content carbohydrate, such as glucose and the like, and electrolytes.
- the nitrogen balance of the body In prolonged states of illness or in injuries and surgical operations, the nitrogen balance of the body must however be considered, i.e. the ratio of nitrogen loss to nitrogen intake.
- the parenteral nutritional support can be supplemented with amino acid supply to improve the nitrogen balance. Different amino acid compositions for parenteral supply are previously known, see e.g.
- the patient Postoperatively, the patient often exhibits loss of appetite, making it difficult to supply nutrition, although there are possibilities, by tube-feeding, of supplying different kinds of nutrient solutions. Since most patients do not tolerate this way of feeding, it becomes necessary to resort to intravenous feeding.
- the nutrition substrates available for energy metabolism are various sugar solutions and fatty emulsions, which today seem appropriate.
- the amino acid solutions available are inadequate, both because it is not possible to add tyrosine in sufficient amounts since this is a relatively insoluble amino acid, and because certain important amide derivatives of amino acids (glutamine and asparagine) cannot be included. This is due to difficulties in heat-sterilising solutions of such amides, and also to the fact that the amides are unstable when stored.
- said vital amide derivatives can be brought into a form suitable for administration by sterile filtration of an aqueous solution, followed by rapid cooling and cold storage limited to a few months.
- One alternative is freeze-drying the sterile-filtered solution, yielding a sterile powder.
- this powder can be added to a conventional amino acid mixture.
- other forms of powder sterilisation, not relying on heat, are conceivable.
- the possibility of using the Na salt of the compounds in order to increase the solubility has also been considered.
- the invention thus relates to a composition for therapeutic, especially postoperative and posttraumatic, parenteral nutritional support treatment, which composition is based on a conventional amino acid mixture, the composition comprising L-glutamine and/or alpha- ketoglutarate, and optionally L-asparagine and/or acetoacetate, the components of the composition, expressed in g dry component/l aqueous solution, being: the composition being characterised in that it also contains 5-30 g/l L-glutamine and/or 5-25 g/l alpha- ketoglutarate, and optionally 0.5-10 g/l L-asparagine and optionally 0.5-10 g/l acetoacetate, or salts or esters thereof.
- a preferred amount of L-glutamine in the composition of the present invention is 10-30 g/l and an especially preferred amount is 15-25 g/l, specifically 20 g/l.
- a preferred amount of alpha-ketoglutarate in the composition of the present invention is 10-25 g/l, specifically 16.5 g/l.
- compositions have included the following suitable components (expressed in g dry component/l aqueous solution):
- alpha-ketoglutarate When alpha-ketoglutarate should be included in the composition, it must be added in the form of its sodium salt or its esters, since it is otherwise extremely sparingly soluble.
- the glutamine can also be added in the form of the sodium salt thereof, thus improving its solubility.
- the invention also relates to the use of L-glutamine and/or its derivative alpha-ketoglutarate and optionally L-asparagine and/or acetoacetate for the preparation of a composition intended for therapeutic, especially postoperative and posttraumatic, parenteral nutritional support treatment, which use is characterised in that L-glutamine and/or alpha-ketoglutarate and optionally L-asparagine and/or acetoacetate or salts or esters thereof, dissolved in water and sterile-filtered, are added in cold-stored and freeze-dried form or other sterile powder form to a commercial amino acid nutrient solution immediately before the therapeutic treatment.
- L-glutamine, alpha-ketoglutarate and optionally L-asparagine and/or acetoacetate or salts or esters thereof are dissolved in sterile pyrogen-free water at 30-50°C.
- the solution is sterile-filtered and rapidly cooled and may thereafter be stored for a few months in a solution in a cooled state or for an even longer time in the frozen state, or stored after freeze-drying for several years in sterile powder form, until it should be used together with an amino acid solution of conventional commercial type, for instance of the Vamin® type (amino acid nutrient composition from KabiVitrum AB).
- Carbohydrates and fatty substances can also be added to the infusion solution. When using alpha-ketogutarate, this must be added in the form of its sodium salt or its esters, which is also possible, but not necessary, in the case of L-glutamine.
- Urine was collected continuously and analysed for urea content. On the basis hereof, it is possible to calculate the nitrogen balance, see MacKenzie et al, A simple method for estimating nitrogen balance in hospitalized patients: A review and supporting data for a previously proposed technique. J. Am.Col. Nutr. 4 :575-581 (1985). In the control group, the nitrogen balance was clearly negative each day during the measuring period of 3 days while, in the test group, it was statistically less negative, however with a substantial spread of the values for day 2. These values are given in the following Table as means ⁇ deviation.
- the protein synthesis in skeletal muscle was estimated by determining the total ribosome concentration and the percentage proportion of polyribosomes, see Wernerman et al: Size distribution of ribosomes in biopsy specimens of human skeletal muscle during starvation. Metabolism 34, 7:665-669, 1985. In the control group, an appreciable reduction of these values was obtained while, in the test group, they remained substantially unchanged after the surgery, see the following Table where the values relate to day 3.
- the intracellular concentration of glutamine in skeletal muscle was affected by the TPN program containing glutamine.
- the glutamine concentration in mmole/l intracellular water in skeletal muscle prior to surgery and on the third postoperative day was as follows:
- the above Tables show that the nitrogen balance and, thus, the postoperative recovery are favourably affected upon parenteral administration of the claimed composition as compared with the control group receiving a conventional composition.
- the Tables further show that the postoperative obligate reduction of the total ribosome concentration and the percentage proportion of polyribosomes could be prevented in the test group, and that the glutamine reduction in skeletal muscle was lower in the glutamine group.
- test group was also given 0.2 g alpha- ketoglutarate ( ⁇ -KG)/kg body weight/day.
- ⁇ -KG alpha- ketoglutarate
- both groups were given isonitrogenous and isocaloric amounts of amino acid and energy. Electrolytes, tracer metals and vitamins were administered to both groups.
- the glutamine concentration (in mmole/kg wet weight) in skeletal muscle was affected in the following manner.
- the present amino acid nutrient compositions thus have a very favourable effect on postoperative and posttraumatic states since they provide an improved nitrogen balance and unaltered protein synthesis capacity and, hence, promote a considerably quicker and improved recovery of patients than is the case of previously known amino acid nutrient compositions.
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT88850373T ATE81468T1 (de) | 1987-10-29 | 1988-10-28 | Aminosaeure-zusammensetzung als traeger fuer die parenterale ernaehrung. |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE8704217A SE8704217D0 (sv) | 1987-10-29 | 1987-10-29 | Aminosyrakomposition for parenteral neringstillforsel |
| SE8704217 | 1987-10-29 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP0318446A1 true EP0318446A1 (de) | 1989-05-31 |
| EP0318446B1 EP0318446B1 (de) | 1992-10-14 |
Family
ID=20370052
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP88909629A Pending EP0398879A1 (de) | 1987-10-29 | 1988-10-28 | Aminosäurezusammensetzung für parenterale nährmittel und deren verwendung |
| EP88850373A Expired - Lifetime EP0318446B1 (de) | 1987-10-29 | 1988-10-28 | Aminosäure-Zusammensetzung als Träger für die parenterale Ernährung |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP88909629A Pending EP0398879A1 (de) | 1987-10-29 | 1988-10-28 | Aminosäurezusammensetzung für parenterale nährmittel und deren verwendung |
Country Status (10)
| Country | Link |
|---|---|
| EP (2) | EP0398879A1 (de) |
| JP (1) | JP2728134B2 (de) |
| AT (1) | ATE81468T1 (de) |
| AU (1) | AU2623888A (de) |
| CA (1) | CA1314232C (de) |
| DE (1) | DE3875322T2 (de) |
| ES (1) | ES2046331T3 (de) |
| GR (1) | GR3006085T3 (de) |
| SE (1) | SE8704217D0 (de) |
| WO (1) | WO1989003688A1 (de) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0509066A1 (de) * | 1990-09-10 | 1992-10-21 | SHUG, Austin L. | Verwendung von Alanin zur Herstellung einer pharmazeutischen Zubereitung zum Schutz des Herzens vor Ischemie. |
| WO1993005780A1 (en) * | 1991-09-27 | 1993-04-01 | Board Of Regents, The University Of Texas System | Amino acids containing parenteral formulations for the treatment of hypotension and related pathologies |
| US5286739A (en) * | 1991-09-27 | 1994-02-15 | Board Of Regents, University Of Texas System | Parenteral formulations for the inhibition of systemic hypotension associated with nitric oxide production or endothelial derived relaxing factor |
| US5334380A (en) * | 1991-09-27 | 1994-08-02 | Board Of Regents, The University Of Texas System | Anti-endotoxin, interleukin-1 receptor antagonist and anti-tumor necrosis factor antibody with arginine-free formulations for the treatment of hypotension |
| US5374651A (en) * | 1991-09-27 | 1994-12-20 | Board Of Regents, The University Of Texas System | Methods and compositions for the treatment of hypotension with arginine free essential and essential amino acids and arginine derivatives |
| EP0649304A1 (de) * | 1992-07-17 | 1995-04-26 | Brigham And Women's Hospital | Zusammensetzung und verfahren zur verminderung von muskelabbau |
| FR2711529A1 (fr) * | 1993-10-28 | 1995-05-05 | Clintec Nutrition Cy | Composition à base d'acides aminés destinée au traitement d'une infection ou d'une agression engendrant une réaction inflammatoire, chez les animaux et chez l'homme. |
| US6649746B1 (en) | 1999-05-07 | 2003-11-18 | University Of Virginia Patent Foundation | Biological production of stable glutamine, poly-glutamine derivatives in transgenic organisms and their use for therapeutic purposes |
| WO2007122190A1 (en) * | 2006-04-21 | 2007-11-01 | Sgp & Sons Ab | Compositions comprising alpha-ketoglutarate and their use for modulating muscle performance |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8902544L (sv) * | 1989-07-17 | 1991-01-18 | Kabivitrum Ab | Beredning foer naeringstillfoersel, samt saett foer dess framsaellning |
| SE9003844L (sv) * | 1990-12-03 | 1992-06-04 | Kabi Pharmacia Ab | Naeringstillsats |
| GB9121467D0 (en) * | 1991-10-10 | 1991-11-27 | Sandoz Nutrition Ltd | Improvements in or relating to organic compounds |
| US5646187A (en) * | 1992-05-20 | 1997-07-08 | Ab Erik Vinnars | Use of alpha-ketoglutarate |
| SE9201584D0 (sv) * | 1992-05-20 | 1992-05-20 | Vinnars Erik Ab | Use of alpha-ketoglutarate |
| SE9303691D0 (sv) * | 1993-11-09 | 1993-11-09 | Gramineer Ab | New beverage |
| SE9402027D0 (sv) * | 1994-06-10 | 1994-06-10 | Pharmacia Ab | Energy substrates |
| WO1999025331A1 (en) * | 1997-11-13 | 1999-05-27 | University Of Florida | Use of ketoacids together with amino acids for enhancing muscle performance and recovery from fatigue |
| US6905707B2 (en) | 1998-05-28 | 2005-06-14 | Medical Research Institute | Controlled release arginine alpha ketoglutarate |
| US20020147237A1 (en) * | 2001-01-31 | 2002-10-10 | Lars Wiklund | Preservation of bodily protein |
| WO2004096207A1 (ja) * | 2003-04-30 | 2004-11-11 | Ajinomoto Co., Inc. | 体温低下抑制剤 |
| JP4528925B2 (ja) * | 2003-05-30 | 2010-08-25 | 独立行政法人理化学研究所 | アミノ酸組成物及び補液 |
| JPWO2005027898A1 (ja) * | 2003-09-19 | 2007-11-15 | 独立行政法人理化学研究所 | アミノ酸組成物 |
| CN101052390B (zh) | 2004-09-17 | 2011-12-14 | 味之素株式会社 | 功能性消化道障碍预防·改善药以及食品 |
| JP5177785B2 (ja) * | 2004-11-02 | 2013-04-10 | 味の素株式会社 | 周術期患者用薬剤 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1987003806A1 (en) * | 1985-12-18 | 1987-07-02 | Veech Richard L | Parenteral nutrition therapy with amino acids |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5916817A (ja) * | 1982-07-16 | 1984-01-28 | Eisai Co Ltd | アミノ酸輸液 |
| JPS5927817A (ja) * | 1982-08-05 | 1984-02-14 | Tanabe Seiyaku Co Ltd | アミノ酸輸液 |
| JPS6178719A (ja) * | 1984-09-25 | 1986-04-22 | Tanabe Seiyaku Co Ltd | 総合輸液剤 |
| JPS62221621A (ja) * | 1986-03-24 | 1987-09-29 | Tanabe Seiyaku Co Ltd | 総合輸液剤 |
-
1987
- 1987-10-29 SE SE8704217A patent/SE8704217D0/xx unknown
-
1988
- 1988-10-28 AU AU26238/88A patent/AU2623888A/en not_active Abandoned
- 1988-10-28 EP EP88909629A patent/EP0398879A1/de active Pending
- 1988-10-28 WO PCT/SE1988/000578 patent/WO1989003688A1/en not_active Application Discontinuation
- 1988-10-28 CA CA000581559A patent/CA1314232C/en not_active Expired - Fee Related
- 1988-10-28 ES ES198888850373T patent/ES2046331T3/es not_active Expired - Lifetime
- 1988-10-28 EP EP88850373A patent/EP0318446B1/de not_active Expired - Lifetime
- 1988-10-28 DE DE8888850373T patent/DE3875322T2/de not_active Expired - Fee Related
- 1988-10-28 JP JP63508896A patent/JP2728134B2/ja not_active Expired - Lifetime
- 1988-10-28 AT AT88850373T patent/ATE81468T1/de not_active IP Right Cessation
-
1992
- 1992-10-26 GR GR920402414T patent/GR3006085T3/el unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1987003806A1 (en) * | 1985-12-18 | 1987-07-02 | Veech Richard L | Parenteral nutrition therapy with amino acids |
Non-Patent Citations (1)
| Title |
|---|
| DIALOG 05710808, Medline 86011808; C.R. KAPADIA: "Maintenance of skeletal muscle intracellular glutamine during standard surgical trauma", & J. Parenter Enteral Nutr, Sept-Oct. 1985, vol. 9, (5), p583-9 * |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0509066A1 (de) * | 1990-09-10 | 1992-10-21 | SHUG, Austin L. | Verwendung von Alanin zur Herstellung einer pharmazeutischen Zubereitung zum Schutz des Herzens vor Ischemie. |
| EP0509066A4 (en) * | 1990-09-10 | 1992-11-25 | Austin L. Shug | Composition and method for protecting the heart during reperfusion |
| US5534545A (en) * | 1991-09-27 | 1996-07-09 | Board Of Regents, The University Of Texas System | Parenteral amino acid formulations for the inhibition of systemic hypotension associated with nitric oxide production |
| US5286739A (en) * | 1991-09-27 | 1994-02-15 | Board Of Regents, University Of Texas System | Parenteral formulations for the inhibition of systemic hypotension associated with nitric oxide production or endothelial derived relaxing factor |
| US5334380A (en) * | 1991-09-27 | 1994-08-02 | Board Of Regents, The University Of Texas System | Anti-endotoxin, interleukin-1 receptor antagonist and anti-tumor necrosis factor antibody with arginine-free formulations for the treatment of hypotension |
| US5374651A (en) * | 1991-09-27 | 1994-12-20 | Board Of Regents, The University Of Texas System | Methods and compositions for the treatment of hypotension with arginine free essential and essential amino acids and arginine derivatives |
| WO1993005780A1 (en) * | 1991-09-27 | 1993-04-01 | Board Of Regents, The University Of Texas System | Amino acids containing parenteral formulations for the treatment of hypotension and related pathologies |
| EP0649304A1 (de) * | 1992-07-17 | 1995-04-26 | Brigham And Women's Hospital | Zusammensetzung und verfahren zur verminderung von muskelabbau |
| EP0649304A4 (de) * | 1992-07-17 | 1999-09-15 | Brigham & Womens Hospital | Zusammensetzung und verfahren zur verminderung von muskelabbau. |
| FR2711529A1 (fr) * | 1993-10-28 | 1995-05-05 | Clintec Nutrition Cy | Composition à base d'acides aminés destinée au traitement d'une infection ou d'une agression engendrant une réaction inflammatoire, chez les animaux et chez l'homme. |
| EP0655244A1 (de) * | 1993-10-28 | 1995-05-31 | Clintec Nutrition Company | Zusammensetzungen aus Aminosäure zur Behandlung von Infektionen |
| US6649746B1 (en) | 1999-05-07 | 2003-11-18 | University Of Virginia Patent Foundation | Biological production of stable glutamine, poly-glutamine derivatives in transgenic organisms and their use for therapeutic purposes |
| WO2007122190A1 (en) * | 2006-04-21 | 2007-11-01 | Sgp & Sons Ab | Compositions comprising alpha-ketoglutarate and their use for modulating muscle performance |
Also Published As
| Publication number | Publication date |
|---|---|
| ATE81468T1 (de) | 1992-10-15 |
| SE8704217D0 (sv) | 1987-10-29 |
| GR3006085T3 (de) | 1993-06-21 |
| ES2046331T3 (es) | 1994-02-01 |
| EP0318446B1 (de) | 1992-10-14 |
| AU2623888A (en) | 1989-05-23 |
| EP0398879A1 (de) | 1990-11-28 |
| JPH03500775A (ja) | 1991-02-21 |
| WO1989003688A1 (en) | 1989-05-05 |
| CA1314232C (en) | 1993-03-09 |
| DE3875322T2 (de) | 1993-05-13 |
| DE3875322D1 (de) | 1992-11-19 |
| JP2728134B2 (ja) | 1998-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0318446B1 (de) | Aminosäure-Zusammensetzung als Träger für die parenterale Ernährung | |
| US5039704A (en) | Method of treating catabolic dysfunction | |
| US5576287A (en) | Method for treating acute renal disease and failure | |
| DE2556100C2 (de) | ||
| JPH0920678A (ja) | 腎臓衰弱治療用組成物及び方法 | |
| EP0238553B1 (de) | Behandlungsverfahren kataboler dysfunktion | |
| CA2140361C (en) | Composition and methods for decreasing muscle breakdown | |
| Petersson et al. | Long‐term effect of glycyl‐glutamine after elective surgery on free amino acids in muscle | |
| Kopple et al. | Nitrogen balance and plasma amino acid levels in uremic patients fed an essential amino acid diet | |
| US5646187A (en) | Use of alpha-ketoglutarate | |
| US5310768A (en) | Method for improving the glutamine content in skeletal muscle and composition therefore | |
| Karner et al. | Alanyl-glutamine infusions to patients with acute pancreatitis | |
| AU661399B2 (en) | Use of alpha-ketoglutarate | |
| JP3137273B2 (ja) | 糖尿病に有効な組成物 | |
| LoDER et al. | What rate of infusion of intravenous nutrition solution is required to stimulate uptake of amino acids by peripheral tissues in depleted patients? | |
| EP0355453A2 (de) | Verwendung von 3-Hydroxy-Buttersäure als Energiequelle | |
| EP0076841A1 (de) | Verbesserte lösung für parenterale nährung | |
| JPH09110686A (ja) | マクロファージ一酸化窒素産生亢進剤 | |
| JP3429327B2 (ja) | 癌用アミノ酸輸液剤 | |
| Jeevanandam et al. | Altered tissue polyamine levels due to ornithine-α-ketoglutarate in traumatized growing rats | |
| Thompson et al. | Relationship of jejunostomy and urine polyamine content to refeeding and intestinal structure and function | |
| Freund et al. | The effect of different intravenous nutritional regimens on renal function during acute renal failure in the rat | |
| JPH02138952A (ja) | Ｌ−ロイシンのジペプチドを含有する栄養輸液組成物 | |
| Jeevanandam et al. | Amelioration of the protein metabolic response in spermidine-supplemented trauma rats | |
| Goulet et al. | Parenteral nutrition in infants and children |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): ES GR |
|
| 17P | Request for examination filed |
Effective date: 19890526 |
|
| 17Q | First examination report despatched |
Effective date: 19900831 |
|
| RBV | Designated contracting states (corrected) |
Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE |
|
| XX | Miscellaneous (additional remarks) |
Free format text: VERBUNDEN MIT 88909629.3/0398879 (EUROPAEISCHE ANMELDENUMMER/VEROEFFENTLICHUNGSNUMMER) DURCH ENTSCHEIDUNG VOM 25.03.91. |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE |
|
| REF | Corresponds to: |
Ref document number: 81468 Country of ref document: AT Date of ref document: 19921015 Kind code of ref document: T |
|
| XX | Miscellaneous (additional remarks) |
Free format text: VERBUNDEN MIT 88909629.3/0398879 (EUROPAEISCHE ANMELDENUMMER/VEROEFFENTLICHUNGSNUMMER) DURCH ENTSCHEIDUNG VOM 25.03.91. |
|
| ITF | It: translation for a ep patent filed | ||
| REF | Corresponds to: |
Ref document number: 3875322 Country of ref document: DE Date of ref document: 19921119 |
|
| ET | Fr: translation filed | ||
| REG | Reference to a national code |
Ref country code: GR Ref legal event code: FG4A Free format text: 3006085 |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| 26N | No opposition filed | ||
| EPTA | Lu: last paid annual fee | ||
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2046331 Country of ref document: ES Kind code of ref document: T3 |
|
| EAL | Se: european patent in force in sweden |
Ref document number: 88850373.7 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20001016 Year of fee payment: 13 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20001017 Year of fee payment: 13 Ref country code: BE Payment date: 20001017 Year of fee payment: 13 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20001020 Year of fee payment: 13 Ref country code: FR Payment date: 20001020 Year of fee payment: 13 Ref country code: DE Payment date: 20001020 Year of fee payment: 13 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GR Payment date: 20001023 Year of fee payment: 13 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20001024 Year of fee payment: 13 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20001025 Year of fee payment: 13 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20001026 Year of fee payment: 13 Ref country code: ES Payment date: 20001026 Year of fee payment: 13 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20011028 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20011028 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20011028 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20011029 Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20011029 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20011031 Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20011031 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20011031 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20011031 |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
| BERE | Be: lapsed |
Owner name: ERIK VINNARS A.B. Effective date: 20011031 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20020501 |
|
| EUG | Se: european patent has lapsed |
Ref document number: 88850373.7 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
| GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20011028 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20020628 |
|
| NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee |
Effective date: 20020501 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20020702 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20021113 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20051028 |